Latest news
25 items- SECSEC Form 15-12G filed by Allakos Inc.15-12G - Allakos Inc. (0001564824) (Filer)
- INSIDERLarge owner Bvf Partners L P/Il returned 16,312,872 shares to the company (SEC Form 4)4 - Allakos Inc. (0001564824) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Allakos Inc.SCHEDULE 13G/A - Allakos Inc. (0001564824) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Allakos Inc.SCHEDULE 13D/A - Allakos Inc. (0001564824) (Subject)
- SECSEC Form EFFECT filed by Allakos Inc.EFFECT - Allakos Inc. (0001564824) (Filer)
- SECSEC Form EFFECT filed by Allakos Inc.EFFECT - Allakos Inc. (0001564824) (Filer)
- SECSEC Form S-8 POS filed by Allakos Inc.S-8 POS - Allakos Inc. (0001564824) (Filer)
- SECSEC Form S-8 POS filed by Allakos Inc.S-8 POS - Allakos Inc. (0001564824) (Filer)
- SECSEC Form S-8 POS filed by Allakos Inc.S-8 POS - Allakos Inc. (0001564824) (Filer)
- SECSEC Form S-8 POS filed by Allakos Inc.S-8 POS - Allakos Inc. (0001564824) (Filer)
- SECSEC Form S-8 POS filed by Allakos Inc.S-8 POS - Allakos Inc. (0001564824) (Filer)
- SECSEC Form S-8 POS filed by Allakos Inc.S-8 POS - Allakos Inc. (0001564824) (Filer)
- SECSEC Form S-8 POS filed by Allakos Inc.S-8 POS - Allakos Inc. (0001564824) (Filer)
- SECSEC Form S-8 POS filed by Allakos Inc.S-8 POS - Allakos Inc. (0001564824) (Filer)
- SECSEC Form POS AM filed by Allakos Inc.POS AM - Allakos Inc. (0001564824) (Filer)
- SECSEC Form POS AM filed by Allakos Inc.POS AM - Allakos Inc. (0001564824) (Filer)
- INSIDERDirector Walker Paul Edward returned 6,147,260 shares to the company (SEC Form 4)4 - Allakos Inc. (0001564824) (Issuer)
- INSIDERPresident Tomasi Adam returned 533,420 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Allakos Inc. (0001564824) (Issuer)
- INSIDERSEC Form 4 filed by Director Thomas Dolca4 - Allakos Inc. (0001564824) (Issuer)
- INSIDERChief Financial Officer Radford Harlan Baird returned 163,426 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Allakos Inc. (0001564824) (Issuer)
- INSIDERSEC Form 4 filed by Director Ladd Amy L4 - Allakos Inc. (0001564824) (Issuer)
- INSIDERSEC Form 4 filed by Director James Steven P4 - Allakos Inc. (0001564824) (Issuer)
- INSIDERSEC Form 4 filed by Director Graham Neil Murray Hamilton4 - Allakos Inc. (0001564824) (Issuer)
- INSIDERSEC Form 4 filed by Director Andreatta Robert E4 - Allakos Inc. (0001564824) (Issuer)
- INSIDERChief Executive Officer Alexander Robert returned 1,058,404 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Allakos Inc. (0001564824) (Issuer)
ALLK FAQ
7 questionsWhat does Allakos Inc. do?
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.Where does ALLK stock trade?
Allakos Inc. (ALLK) is listed on NASDAQ.What sector and industry is ALLK in?
Allakos Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Allakos Inc. go public?
Allakos Inc. (ALLK) completed its IPO in 2018.What are analysts saying about ALLK?
Allakos Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold with a $150.00 price target on 2024-01-17.What companies are similar to ALLK?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALLK side-by-side with any of them on Quantisnow.How can I track ALLK on Quantisnow?
Quantisnow aggregates Allakos Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALLK to receive live email and push alerts on every new disclosure.